Aventis Streamlines R&D
Pharmaceutical Executive
Aventis announced plans to cut R&D costs by spinning out a stake in one of its research units. The private equity house Warburg Pincus will invest 60 million euro in ProSkelia, taking a 58 percent share.
Aventis announced plans to cut R&D costs by spinning out a stake in one of its research units. The private equity house Warburg Pincus will invest 60 million euro in ProSkelia, taking a 58 percent share. Aventis will retain the other 42 percent. ProSkelia, based in Romainville, near Paris, France, special-izes in early-stage research into treatments for bone disease.
Aventis also intends to spin off its gene therapy unit, Gencell, but it has yet to find a partner that is prepared to meet its valuation. Attempts to reduce research cash burn follow Aventis' discontinuation of trials for two of the company's pipeline compounds. Development of the ACE/NEP (angiotensin con-verting enzyme/neutral endopeptidase) inhibitor M100,240 for the treatment of hypertension was stopped after a Phase II clinical trial yielded disappointing results. Aventis says it intends to examine the drug's possibilities in other therapeutic uses.
It has also terminated a co-development agreement with ViroPharma of Exton, Penn-sylvania, for the antiviral agent Picovir (pleconaril), intended to treat the common cold. FDA issued a non-approvable letter for it in May.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
